Tong-Ming Fu

Prof. Tong-Ming Fu

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2017 in npj Vaccines
Verified
Journal Article
Open access
PDF file
GSGeorgina Salazar
Georgina Salazar
NZNingyan Zhang
Ningyan Zhang
TFTong-Ming Fu
Tong-Ming Fu
ZAZhiqiang An
Zhiqiang An
Antibodies are an important component in host immune responses to viral pathogens. Because of their unique maturation process, antibodies can evolve to be highly specific to viral antigens. Physicians and researchers have been relying on such high specificity in their quest to understand host–viral interaction and viral pathogenesis mechanisms and to find potential cures for viral infection and disease. With more than 60 recombinant monoclonal antibodies developed for human use in the last 20 years, monoclonal antibodies are now considered a viable therapeutic modality for infectious disease targets, including newly emerging viral pathogens such as Ebola representing heightened public health concerns, as well as pathogens that have long been known, such as human cytomegalovirus. Here, we summarize some recent advances in identification and characterization of monoclonal antibodies suitable as drug candidates for clinical evaluation, and review some promising candidates in the development pipeline.

2 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DFDaniel C. Freed
Daniel C. Freed
QTQi Tang
Qi Tang
ATAimin Tang
Aimin Tang
FLFengsheng Li
Fengsheng Li
XHXi He
Xi He
TFTong-Ming Fu
Tong-Ming Fu
Significance: Congenital human cytomegalovirus (HCMV) infection is an important cause of newborn disability, and developing a vaccine against congenital HCMV is a top priority. However, despite decades of efforts, a vaccine remains elusive. Previous vaccines lacked an antigen called pentameric glycoprotein H (gH) complex, essential for the virus to infect epithelial/endothelial cells, and these vaccines induced poor neutralizing antibodies. To support a unique vaccine concept featuring the pentameric gH complex, we established 45 mAbs from a rabbit immunized with an experimental vaccine. Over 50% of the mAbs have antiviral activity, and potent clones target the pentameric gH complex, thus establishing this antigen as the key for potent antiviral antibodies by vaccination. Our result contributes to the understanding of immune attributes of an effective vaccine against HCMV.

26 October 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DWDai Wang
Dai Wang
DFDaniel C. Freed
Daniel C. Freed
XHXi He
Xi He
FLFengsheng Li
Fengsheng Li
ATAimin Tang
Aimin Tang
TFTong-Ming Fu
Tong-Ming Fu
Congenital human cytomegalovirus (HCMV) infection occurs in ~0.64% of infants born each year in the United States and is the leading nongenetic cause of childhood neurodevelopmental disabilities. No licensed HCMV vaccine is currently available. Natural immunity to HCMV in women before pregnancy is associated with a reduced risk of fetal infection, suggesting that a vaccine is feasible if it can reproduce immune responses elicited by natural infection. On the basis of this premise, we developed a whole-virus vaccine candidate from the live attenuated AD169 strain, with genetic modifications to improve its immunogenicity and attenuation. We first restored the expression of the pentameric gH/gL/pUL128-131 protein complex, a major target for neutralizing antibodies in natural immunity. We then incorporated a chemically controlled protein stabilization switch in the virus, enabling us to regulate viral replication with a synthetic compound named Shield-1. The virus replicated as efficiently as its parental virus in the presence of Shield-1 but failed to produce progeny upon removal of the compound. The vaccine was immunogenic in multiple animal species and induced durable neutralizing antibodies, as well as CD4+ and CD8+ T cells, to multiple viral antigens in nonhuman primates.

1 February 2009 in Vaccine
Verified
Journal Article
Closed access
TFTong-Ming Fu
Tong-Ming Fu
KGKaren M. Grimm
Karen M. Grimm
MCMichael P. Citron
Michael P. Citron
DFDaniel C. Freed
Daniel C. Freed
JFJiang Fan
Jiang Fan
JJJoseph G. Joyce
Joseph G. Joyce

19 April 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KKKirill V. Kalnin
Kirill V. Kalnin
TPTimothy Plitnik
Timothy Plitnik
MKMichael Kishko
Michael Kishko
JZJinrong Zhang
Jinrong Zhang
DZDonghui Zhang
Donghui Zhang
DCDanilo Casimiro
Danilo Casimiro
Emergency use authorization of COVID vaccines has brought hope to mitigate pandemic of coronavirus disease 2019 (COVID-19). However, there remains a need for additional effective vaccines to meet the global demand and address the potential new viral variants. mRNA technologies offer an expeditious path alternative to traditional vaccine approaches. Here we describe the efforts to utilize an mRNA platform for rational design and evaluations of mRNA vaccine candidates based on the spike (S) glycoprotein of SARS-CoV-2. Several mRNA constructs of S-protein, including wild type, a pre-fusion stabilized mutant (2P), a furin cleavage-site mutant (GSAS) and a double mutant form (2P/GSAS), as well as others, were tested in animal models for their capacity to elicit neutralizing antibodies (nAbs). The lead 2P/GSAS candidate was further assessed in dose-ranging studies in mice and Cynomolgus macaques, and for efficacy in a Syrian golden hamster model. The selected 2P/GSAS vaccine formulation, designated MRT5500, elicited potent nAbs as measured in neutralization assays in all three preclinical models and more importantly, protected against SARS-CoV-2-induced weight loss and lung pathology in hamsters. In addition, MRT5500 elicited TH1-biased responses in both mouse and non-human primate (NHP), thus alleviating a hypothetical concern of potential vaccine-associated enhanced respiratory diseases known associated with TH2-biased responses. These data position MRT5500 as a viable vaccine candidate for entering clinical development.

1 April 1999 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TFTong-Ming Fu
Tong-Ming Fu
LGLiming Guan
Liming Guan
AFArthur Friedman
Arthur Friedman
TSTimothy L. Schofield
Timothy L. Schofield
JUJeffrey B. Ulmer
Jeffrey B. Ulmer
JDJohn J. Donnelly
John J. Donnelly
Intramuscular injection of BALB/c mice with a DNA plasmid encoding nucleoprotein (NP) from influenza virus A/PR/8/34 (H1N1) provides cross-strain protection against lethal challenge with influenza virus A/HK/68 (H3N2). CTL specific for the H-2Kd-restricted epitope NP147–155 are present in these mice and are thought to play a role in the protection. To assess the effectiveness of NP DNA immunization in comparison with influenza virus infection in the induction of CTL responses, we monitored the frequency of CTL precursors (CTLp) in mice following i.m. injection with NP DNA or intranasal infection with influenza virus and showed that the CTLp frequency in NP DNA-immunized mice can reach levels found in mice that had been infected with influenza virus. We also measured the CTLp frequency, anti-NP Ab titers, and T cell proliferative responses in mice that were injected with titrated dosages of NP DNA and documented a correlation of the CTLp frequency and the Ab titers, but not proliferative responses, with the injection dose. Furthermore, we observed a positive correlation between the frequency of NP147–155 epitope-specific CTLp and the extent of protective immunity against cross-strain influenza challenge induced by NP DNA injection. Collectively, these results and our early observations from adoptive transfer experiments of in vitro activated lymphocytes from NP DNA-immunized mice suggest a protective function of NP-specific CTLp in mice against cross-strain influenza virus challenge.